FDA clears Mylan's generic transdermal system for hypertension

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The FDA has given the green light to Mylan Technologies' abbreviated new drug application for its Clonidine Transdermal System, a generic version of the Catapres-TTS system (Boehringer Ingelheim) used to treat hypertension.

Pittsburgh-based Mylan said the Clonindine Transdermal System will be available in 0.1 mg per day, 0.2 mg per day and 0.3 mg per day dosages and is currently available for shipment.

According to Mylan, the Clonindine Transdermal System saw $313 million in sales for 12 months, which ended March 31.